Tao-nan Chi, MD | |
761 Main Ave, Suite 201, Norwalk, CT 06851-1080 | |
(203) 838-4000 | |
(203) 845-9535 |
Full Name | Tao-nan Chi |
---|---|
Gender | Male |
Speciality | Internal Medicine |
Experience | 54 Years |
Location | 761 Main Ave, Norwalk, Connecticut |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1538279583 | NPI | - | NPPES |
004187466 | Medicaid | CT |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0000X | Internal Medicine - Cardiovascular Disease | 019430 (Connecticut) | Secondary |
207R00000X | Internal Medicine | 019430 (Connecticut) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Greenwich Hospital Association - | Greenwich, CT | Hospital |
St. Vincent's Medical Center | Bridgeport, CT | Hospital |
Norwalk Hospital | Norwalk, CT | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Hartford Healthcare Medical Group Specialists Pllc | 3173866241 | 1138 |
News Archive
The Food and Drug Administration in the United States is coming under increasing pressure to enforce tougher regulations on the amount of sodium in food.
The Weizmann Institute of Science in Rehovot, Israel today announced major scientific instrument purchases from Bruker (NASDAQ: BRKR), including a novel Aeon™ 1GHz nuclear magnetic resonance (NMR) system for expanding frontiers in structural biology and intrinsically disordered protein (IDPs) research. Furthermore, the Weizmann Institute is adding an Aeon 600 MHz NMR, a 263 GHz dynamic nuclear polarization (DNP)-NMR system, and a Biospec® 15 Tesla system for preclinical ultra-high field magnetic resonance imaging (MRI). Various NMR and electron paramagnetic resonance (EPR) instrument upgrades round out this major acquisition, instantly propelling the Weizmann Institute to the frontiers of modern magnetic resonance research infrastructure.
VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced the results of the Oncologic Drugs Advisory Committee (ODAC) Meeting at which data for its lead oncology therapeutic Onrigin(TM)(laromustine) Injection were presented for the indication of remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML).
Today, Advanced BioScience Laboratories, Inc. (ABL) and the University of Massachusetts Medical School (UMMS) report that their unique HIV vaccine formulation was effective in eliciting strong and balanced immune responses in healthy human volunteers.
A gene crucial for embryonic development can quickly become a potent cancer promoter in adult mice after a genetic misalignment, according to researchers from Fox Chase Cancer Center, causing white blood cells to become cancerous spontaneously.
› Verified 8 days ago
Entity Name | Soundview Medical Associates Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1306805130 PECOS PAC ID: 4587563788 Enrollment ID: O20040107000456 |
News Archive
The Food and Drug Administration in the United States is coming under increasing pressure to enforce tougher regulations on the amount of sodium in food.
The Weizmann Institute of Science in Rehovot, Israel today announced major scientific instrument purchases from Bruker (NASDAQ: BRKR), including a novel Aeon™ 1GHz nuclear magnetic resonance (NMR) system for expanding frontiers in structural biology and intrinsically disordered protein (IDPs) research. Furthermore, the Weizmann Institute is adding an Aeon 600 MHz NMR, a 263 GHz dynamic nuclear polarization (DNP)-NMR system, and a Biospec® 15 Tesla system for preclinical ultra-high field magnetic resonance imaging (MRI). Various NMR and electron paramagnetic resonance (EPR) instrument upgrades round out this major acquisition, instantly propelling the Weizmann Institute to the frontiers of modern magnetic resonance research infrastructure.
VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced the results of the Oncologic Drugs Advisory Committee (ODAC) Meeting at which data for its lead oncology therapeutic Onrigin(TM)(laromustine) Injection were presented for the indication of remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML).
Today, Advanced BioScience Laboratories, Inc. (ABL) and the University of Massachusetts Medical School (UMMS) report that their unique HIV vaccine formulation was effective in eliciting strong and balanced immune responses in healthy human volunteers.
A gene crucial for embryonic development can quickly become a potent cancer promoter in adult mice after a genetic misalignment, according to researchers from Fox Chase Cancer Center, causing white blood cells to become cancerous spontaneously.
› Verified 8 days ago
Entity Name | Hartford Healthcare Medical Group Specialists Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1023584216 PECOS PAC ID: 3173866241 Enrollment ID: O20190514001441 |
News Archive
The Food and Drug Administration in the United States is coming under increasing pressure to enforce tougher regulations on the amount of sodium in food.
The Weizmann Institute of Science in Rehovot, Israel today announced major scientific instrument purchases from Bruker (NASDAQ: BRKR), including a novel Aeon™ 1GHz nuclear magnetic resonance (NMR) system for expanding frontiers in structural biology and intrinsically disordered protein (IDPs) research. Furthermore, the Weizmann Institute is adding an Aeon 600 MHz NMR, a 263 GHz dynamic nuclear polarization (DNP)-NMR system, and a Biospec® 15 Tesla system for preclinical ultra-high field magnetic resonance imaging (MRI). Various NMR and electron paramagnetic resonance (EPR) instrument upgrades round out this major acquisition, instantly propelling the Weizmann Institute to the frontiers of modern magnetic resonance research infrastructure.
VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced the results of the Oncologic Drugs Advisory Committee (ODAC) Meeting at which data for its lead oncology therapeutic Onrigin(TM)(laromustine) Injection were presented for the indication of remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML).
Today, Advanced BioScience Laboratories, Inc. (ABL) and the University of Massachusetts Medical School (UMMS) report that their unique HIV vaccine formulation was effective in eliciting strong and balanced immune responses in healthy human volunteers.
A gene crucial for embryonic development can quickly become a potent cancer promoter in adult mice after a genetic misalignment, according to researchers from Fox Chase Cancer Center, causing white blood cells to become cancerous spontaneously.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Tao-nan Chi, MD 761 Main Ave, Suite 201, Norwalk, CT 06851-1080 Ph: (203) 838-4000 | Tao-nan Chi, MD 761 Main Ave, Suite 201, Norwalk, CT 06851-1080 Ph: (203) 838-4000 |
News Archive
The Food and Drug Administration in the United States is coming under increasing pressure to enforce tougher regulations on the amount of sodium in food.
The Weizmann Institute of Science in Rehovot, Israel today announced major scientific instrument purchases from Bruker (NASDAQ: BRKR), including a novel Aeon™ 1GHz nuclear magnetic resonance (NMR) system for expanding frontiers in structural biology and intrinsically disordered protein (IDPs) research. Furthermore, the Weizmann Institute is adding an Aeon 600 MHz NMR, a 263 GHz dynamic nuclear polarization (DNP)-NMR system, and a Biospec® 15 Tesla system for preclinical ultra-high field magnetic resonance imaging (MRI). Various NMR and electron paramagnetic resonance (EPR) instrument upgrades round out this major acquisition, instantly propelling the Weizmann Institute to the frontiers of modern magnetic resonance research infrastructure.
VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced the results of the Oncologic Drugs Advisory Committee (ODAC) Meeting at which data for its lead oncology therapeutic Onrigin(TM)(laromustine) Injection were presented for the indication of remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML).
Today, Advanced BioScience Laboratories, Inc. (ABL) and the University of Massachusetts Medical School (UMMS) report that their unique HIV vaccine formulation was effective in eliciting strong and balanced immune responses in healthy human volunteers.
A gene crucial for embryonic development can quickly become a potent cancer promoter in adult mice after a genetic misalignment, according to researchers from Fox Chase Cancer Center, causing white blood cells to become cancerous spontaneously.
› Verified 8 days ago
Dr. Eve Block, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 24 Stevens St, Norwalk, CT 06850 Phone: 203-852-2665 Fax: 203-739-8878 | |
Vittoria Gassman, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 120 Connecticut Ave, Norwalk Community Health Center, Norwalk, CT 06854 Phone: 203-899-1770 | |
Dr. Yonatan J Hillman, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 30 Stevens St Ste D, Norwalk, CT 06850 Phone: 203-852-3455 | |
Maria A Martin, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 761 Main Ave, Suite 201, Norwalk, CT 06851 Phone: 203-838-4000 Fax: 203-845-9535 | |
Xiaofei Wei, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 761 Main Ave, Suite 201, Norwalk, CT 06851 Phone: 203-838-4000 Fax: 203-845-9535 | |
Daniel Ethan Boxer, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 24 Stevens St, Norwalk, CT 06850 Phone: 203-845-4811 Fax: 203-845-4897 | |
Dr. Caitlyn Kuwata, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 34 Maple St, Norwalk, CT 06850 Phone: 203-852-2025 |